Journal Mobile Options
Table of Contents
Vol. 66, No. 3, 2004
Issue release date: June 2004
Oncology 2004;66:218–225
(DOI:10.1159/000077998)

Adenosquamous Carcinoma of the Esophagus

Clinicopathologic Study of 18 Cases

Yachida S. · Nakanishi Y. · Shimoda T. · Nimura S. · Igaki H. · Tachimori Y. · Kato H.
aClinical Laboratory Division and bEsophageal Surgery Division, National Cancer Center Hospital and cPathology Division, National Cancer Center Research Institute, Tokyo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: Adenosquamous carcinoma (ASC) of the esophagus is an uncommon form of esophageal cancer. Despite isolated case reports on this tumor type, no large clinicopathologic series appears to have been studied at a single institution. Methods: At our institution, 20 cases of ASC were diagnosed pathologically between 1970 and 2001 (20/2,056 total esophageal cancers; 1.0%). Excluding 2 patients who received preoperative radiation therapy, 18 were selected for review of their clinicopathologic features, including survival time, in comparison with those of patients with conventional squamous cell carcinomas (SCCs; n = 850) and adenocarcinomas (ACs; n = 40) of the esophagus. Results: The location and macroscopic type of the ASCs were similar to those of the SCCs. ASC tumors were significantly smaller than SCC (p = 0.004) and AC (p = 0.012) tumors, and the depth of invasion of ASCs was significantly less than that of SCCs (p = 0.028). Lymphatic permeation and blood vessel invasion were seen in 14 (77.8%) and 7 (38.9%) of the 18 patients with ASCs, respectively, and intraepithelial carcinoma contiguous to the main lesion was evident in 10 cases (56.6%). The cumulative postoperative survival rates of patients with ASC at 3, 5 and 10 years were 71.5, 63.6 and 47.7%, respectively, the outcome being significantly better than for patients with either SCC (p = 0.027) or AC (p = 0.013). Conclusion: In the esophagus, ASCs have better prognosis than conventional SCCs or ACs, probably due to their smaller size and lower stage.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Takamori S, Noguchi M, Morinaga S, Goya T, Tsugane S, Kakegawa T, Shimosato Y: Clinicopathologic characteristics of adenosquamous carcinoma of the lung. Cancer 1991;67:649–654.
  2. Mori M, Iwashita A, Enjoji M: Adenosquamous carcinoma of the stomach: A clinicopathologic analysis of 28 cases. Cancer 1986;57:333–339.
  3. Kardon DE, Thompson LDR, Przygodzki RM, Heffess CS: Adenosquamous carcinoma of the pancreas: A clinicopathologic series of 25 cases. Mod Pathol 2001;14:443–451.
  4. Nishihara K, Nagai E, Izumi Y, Yamaguchi K, Tsuneyoshi M: Adenosquamous carcinoma of the gallbladder: A clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res 1994;85:389–399.
  5. Bombí JA, Riverola A, Bordas JM, Cardesa A: Adenosquamous carcinoma of the esophagus: A case report. Path Res Pract 1991;187:514–519.
  6. Orsatti G, Corvalan AH, Sakurai H, Choi HH: Polypoid adenosquamous carcinoma of the esophagus with prominent spindle cells: Report of a case with immunohistochemical and ultrastructural studies. Arch Pathol Lab Med 1993;117:544–547.
  7. Lam KY, Dickens P, Loke SL, Fok M, Ma L, Wong J: Squamous cell carcinoma of the oesophagus with mucin-secreting component (muco-epidermoid carcinoma and adenosquamous carcinoma): A clinicopathologic study and a review of literature. Eur J Surg Oncol 1994;20:25–31.
  8. Ter RB, Govil YK, Leite L, Infantolino A, Ghabra M, Galan A, Katz PO: Adenosquamous carcinoma in Barrett’s esophagus presenting as pseudoachalasia. Am J Gastroenterol 1999;94:268–270.
  9. Kume K, Abe S, Okubo Y, Ejiri Y, Mutou A, Hakozaki H: Superficial spreading carcinoma involving the whole esophagus. Dig Dis Sci 2001;46:776–778.
  10. Cirillo LC, Mainenti PP, Imbriaco M, Franco R, Gatta G, De Rosa G, Salvatore M: Synchronous primary adenocarcinoma and adenosquamous carcinoma of the esophagus. Eur Radiol 2001;11:1964–1967.
  11. Tsutsui S, Kuwano H, Watanabe M, Kitamura M, Sugimachi K: Resection margin for squamous cell carcinoma of the esophagus. Ann Surg 1995;222:193–202.
  12. Japanese Society for Esophageal Diseases: Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, ed 9. Tokyo, Kanehara, 1999.
  13. Tachibana M, Kinugasa S, Dhar DK, Tabara H, Masunaga R, Kotoh T, Kubota H, Nagasue N: Prognostic factors in T1 and T2 squamous cell carcinoma of the thoracic esophagus. Arch Surg 1999;134:50–54.
  14. Sobin LH, Wittekind C: TNM Classification of Malignant Tumours, ed 5. New York, John Wiley & Sons, 1997.
  15. Johns B: Developmental changes in the oesophageal epithelium in man. J Anat 1952;86:431–442.
  16. Gehan EA, Freireich EJ: Non-randomized controls in cancer clinical trials. N Engl J Med 1974;290:198–203.
  17. Nakanishi Y, Ochiai A, Yamauchi Y, Moriya Y, Yoshimura K, Hirohashi S: Clinical implications of lymph node micrometastases in patients with colorectal cancers: A case control study. Oncology 1999;57:276–280.
  18. Werner M, Flejou JF, Hainaut P, Höfler H, Lambert R, Keller G, Stein HJ: Adenocarcinoma of the oesophagus; in Hamilton SR, Aaltonen LA (eds): World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of the Digestive System. Lyon, IARC Press, 2000, pp 20–26.
  19. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T: Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003;133:486–494.
  20. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA: Value of serial carcinonoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995;75:451–456.
  21. Lewin KJ, Appelman HD: Atlas of Tumor Pathology: Tumors of the Esophagus and Stomach, 3rd series, fascicle 18. Washington, DC, Armed Forces Institute of Pathology, 1995, pp 136–137.
  22. Raphael HA, Ellis FH Jr, Dockerty MB: Primary adenocarcinoma of the esophagus: 18-year review and review of literature. Ann Surg 1966;164:785–796.
  23. Cardesa A, Bombí JA, Pera M, Fernandez PL, Campo E, Pera C, Mohr U: Spectrum of glandular differentiation in experimental carcinoma of the esophagus induced by 2, 6-dimethylnitrosomorpholine under the influence of esophagojejunostomy. Exp Toxicol Pathol 1994;46:41–49.
  24. Pera M, Fernandez PL, Pera M, Palacín A, Cardesa A, Dasenbrock C, Tillman T, Mohr U: Expression of cyclin D1 and p53 and its correlation with proliferative activity in the spectrum of esophageal carcinomas induced after duodenal content reflux and 2, 6-dimethylnitrosomorpholine administration in rats. Carcinogenesis 2001;22:271–277.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50